Healthcare sector | Medical Devices industry
| Price | $8.94 |
|---|---|
| Shares Outstanding | 77.94M |
| All-Time Low | $1.36 |
| 52-Week Low | $10.60 |
| Net Cash / Share | $0 |
|---|---|
| Net Current Assets / Share | $-17.95 |
| Net Tangible Assets / Share | $0 |
| Shares Outstanding Ave Change (Annual) | -3.06% |
| Shares Δ YoY | -1.29% |
| Avg CA Burn (Annual %) | -2.00% (as of 3-8-2026) |
| Avg CA Burn (Quarterly %) | 1.76% (as of 3-8-2026) |
| Max Earning Power / Share | $8.12 |
|---|---|
| Adjusted Earning Power |
$-0.21
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
5.34%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 304M (as of 3-8-2026) |
| Avg EBITDA (5Q) | 45.2M (as of 3-8-2026) |
| Avg Net Income (5Y) | 102.6M (as of 3-8-2026) |
| Avg Net Income (5Q) | -99.4M (as of 3-8-2026) |
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | No | 3-8-2026 |
| Consecutive Years Paid | No | 3-8-2026 |
| Pays Dividend | No | 3-8-2026 |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | Yes | 3-8-2026 |
| Net Income Positive | No | 3-8-2026 |
| Current Dividend Streak | No | 3-8-2026 |
Pick a metric to view its history table and chart.
Formula: Tangible Book Value / shares from balance statements. Includes 6 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-12-31 | Quarterly | $-9.07 | -706.4M ($-706,357,000) | 77.9M (77,887,000) |
| 2025-09-30 | Quarterly | $-9.48 | -737.8M ($-737,770,000) | 77.8M (77,835,000) |
| 2025-06-30 | Quarterly | $-9.83 | -765.8M ($-765,846,000) | 77.9M (77,921,000) |
| 2025-03-31 | Quarterly | $-9.89 | -768.8M ($-768,782,000) | 77.7M (77,712,000) |
| 2024-12-31 | Quarterly | $-9.84 | -759.3M ($-759,260,000) | 77.2M (77,164,000) |
| 2024-12-31 | Annual | $-9.84 | -759.3M ($-759,260,000) | 77.2M (77,164,000) |
| 2024-09-30 | Quarterly | $-10.43 | -804.5M ($-804,496,000) | 77.1M (77,134,000) |
| 2023-12-31 | Annual | $-6.85 | -535.4M ($-535,411,000) | 78.2M (78,169,000) |
| 2022-12-31 | Annual | $-4.32 | -361.1M ($-361,087,000) | 83.7M (83,654,000) |
| 2021-12-31 | Annual | $-5.60 | -474.2M ($-474,227,000) | 84.7M (84,701,000) |
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2024-12-31 | 1.6B ($1,610,527,000) |
| 2023-12-31 | 1.5B ($1,541,573,000) |
| 2022-12-31 | 1.6B ($1,557,666,000) |
| 2021-12-31 | 1.5B ($1,542,448,000) |
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| No dividend payment history available yet | |
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2026-03-05 | 77,937,208 | +45,097 |
| 2025-11-03 | 77,892,111 | -18,679 |
| 2025-09-17 | 77,910,790 | -10 |
| 2025-08-04 | 77,910,800 | +198,496 |
Latest short-interest change: 7,477,175 shares (15.60% of float) | Days to cover: 9.57
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-03-12 | 7,477,175 shares | -111,431 | -1.47% |
| 2026-03-02 | 7,588,606 shares | -42,948 | -0.56% |
| 2026-02-11 | 7,631,554 shares | +200,917 | +2.70% |
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| No interesting volume events | ||||
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.